证券代码：600422 证券简称：昆药集团 公告编号：2025-056号 关联监事钟江先生、邵金锋先生回避表决此议案。 此议案审议通过，还须提交公司股东大会审议。 特此公告。 昆药集团股份有限公司监事会 2025 年 12 月 10 日 昆药集团股份有限公司十一届八次监事会决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 昆药集团股份有限公司（以下简称"昆药集团"、"公司"）于 2025 年 12 月 9 日 以通讯表决方式召开公司十一届八次监事会会议。会议通知以书面方式于 2025 年 12 月 5 日发出。会议由公司监事会主席钟江先生召集并主持，本次会议应参加表决监事 5 人，实际参加表决 5 人，符合《公司法》和《公司章程》的规定。会议审议并通过 了以下决议： 1、 关于公司 2026 年日常关联交易预估的议案（详见《昆药集团关于 2026 年日常关 联交易预估的公告》） 同意：3 票 反对：0 票 弃权：0 票 1 ...

证券代码：600422 证券简称：昆药集团 公告编号：2025-055号 昆药集团股份有限公司十一届十一次董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 昆药集团股份有限公司（以下简称"昆药集团"、"公司"）于 2025 年 12 月 9 日以通讯表决方式召开公司十一届十一次董事会会议。会议通知以书面方式于 2025 年 12 月 5 日发出。会议由公司董事长吴文多先生召集并主持，本次会议应参加表决 董事 9 人，实际参加表决 9 人，符合《公司法》和《公司章程》的规定。会议以记名 方式投票表决，审议并通过以下决议： 1、 关于修订《公司章程》的议案（详见《昆药集团关于修订<公司章程>的公告》） 待公司股东大会审议通过修订《公司章程》事项后，公司监事会将停止履职，公 司十一届监事会全体监事自动解任，公司《监事会议事规则》相应废止。在公司股东 大会审议通过取消监事会事项之前，公司十一届监事会仍将严格按照有关法律、法规 和《公司章程》的规定继续履行监督职能，维护公司和全体股东利益。公司监事会的 全体监事在任职期间勤 ...

南财智讯12月9日电，昆药集团公告，公司董事会于近日收到副总裁贺明先生提交的辞职报告。贺明先 生因工作调整，提请辞去公司副总裁职务。辞任后，贺明先生继续担任公司党委专职副书记。根据有关 规定，贺明先生的辞职申请自辞职报告送达公司董事会时生效。 ...

截至12月8日收盘，青蒿素概念下跌0.51%，位居概念板块跌幅榜前列，板块内，德龙汇能、百花医 药、新和成等跌幅居前。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 共封装光学(CPO) | 4.72 | 天津自贸区 | -0.99 | | F5G概念 | 4.30 | 草甘膦 | -0.86 | | 光纤概念 | 3.67 | 青蒿素 | -0.51 | | 铜缆高速连接 | 3.57 | 煤炭概念 | -0.51 | | 福建自贸区 | 3.44 | 高股息精选 | -0.38 | | PET铜箔 | 3.02 | 超级品牌 | -0.34 | | 海南自贸区 | 3.00 | 金属锌 | -0.32 | | WiFi 6 | 3.00 | 大豆 | -0.31 | | 光刻机 | 3.00 | 啤酒概念 | -0.31 | | 海峡两岸 | 2.98 | 共享单车 | -0.29 | 资金面上看，今日青蒿素概念板块获主力资金净流出0.62亿元，其中，5股获主力资金净流出，净流出 资金居首的是德龙汇能， ...

Core Insights - The National Health Commission reported that 17 provinces in China are experiencing high levels of influenza activity, with a positive rate of 51% for flu virus tests among patients with flu-like symptoms [1] - In response to the urgent need for respiratory health protection during the flu season, Kunming Pharmaceutical Group and Yixintang Pharmaceutical initiated the "Clear Lung Action" campaign to promote public awareness of respiratory health and scientific prevention methods [1] Group 1 - The "Clear Lung Action" event featured interactive activities where citizens learned about health, received themed gifts, and engaged in various functional areas, including a large lung-clearing device that attracted many participants [2] - Medical experts provided insights on the relationship between influenza and lung health, symptom recognition, and scientific prevention methods, while free consultations were offered to the public [2] - Participants could measure their lung capacity and function through the "One Breath Lung Challenge," and learn practical lung health maintenance methods through exercises that combine traditional and modern techniques [2] Group 2 - The core concept of the "Clear Lung Action" is based on Kunming Pharmaceutical Group's flagship product, "Kun Traditional Chinese Medicine Clear Lung Phlegm Pill," which has historical roots dating back to the Song Dynasty and is known for its efficacy in clearing lungs and relieving cough [3] - Kunming Pharmaceutical Group's subsidiary, Kun Traditional Chinese Medicine, is recognized as the "oldest pharmaceutical company" by Guinness World Records and has been awarded the "Chinese Time-Honored Brand" honor [3] - Yixintang, a leading retail pharmacy chain in China, operates over 11,230 stores and serves approximately 210 million customers annually, enhancing the reach of health education initiatives [3] Group 3 - The collaboration between leading pharmaceutical companies and large retail pharmacy chains is advancing health education from one-way communication to interactive engagement, emphasizing preventive health measures in the context of the "Healthy China" strategy [4] - The "Clear Lung Action" effectively integrates traditional Chinese medicine's preventive wisdom with contemporary health management practices to safeguard public respiratory health [4]

Group 1 - The Artemisinin concept index rose by 0.57%, ranking 6th among concept sectors, with six stocks increasing in value, including Delong Huineng, Haizheng Pharmaceutical, and China Resources Double Crane, which rose by 4.38%, 2.49%, and 0.75% respectively [1] - The stocks with the largest declines included Baihua Pharmaceutical, Rundu Co., and Fosun Pharmaceutical, which fell by 2.20%, 0.50%, and 0.15% respectively [1] Group 2 - The main capital flow analysis indicates that the Artemisinin concept sector experienced a net outflow of 73 million yuan, with three stocks receiving net inflows, led by Haizheng Pharmaceutical with a net inflow of 2.9933 million yuan [2] - Other stocks with notable net inflows include Fosun Pharmaceutical and Kunming Pharmaceutical Group, with net inflows of 1.7788 million yuan and 1.4040 million yuan respectively [2] Group 3 - In terms of capital inflow ratios, Kunming Pharmaceutical Group, Haizheng Pharmaceutical, and Fosun Pharmaceutical had the highest net inflow rates at 3.59%, 1.88%, and 0.82% respectively [3] - The capital flow data for the Artemisinin concept shows that Haizheng Pharmaceutical had a daily increase of 2.49% with a turnover rate of 1.25% and a net inflow of 2.9933 million yuan [3] - Conversely, stocks like Rundu Co. and Zhejiang Medicine experienced negative net inflows of -2.35 million yuan and -3.5082 million yuan respectively, with net inflow rates of -4.49% and -5.28% [4]

中国经济网12月1日讯 11月28日，国家医保局发布法院刑事判决书摘录文章《鞍山市双山医院药剂科主任刘某红受贿案》。刘某红利用担任鞍山市双山医院 及鞍山市中心医院立山院区药剂科主任职务上的便利，在釆购药品、增加釆购业务量等方面为他人提供帮助。 记者检索中国裁判文书网发现，此摘录文章源自《某明红受贿一审刑事判决书》。此判决书显示，某明红曾收受医药代表"李某2"20万元。其中，昆药集团 和武汉人福药业有限公司产品代理涉案。 根据判决书，2015年7月至2018年12月，被告人某明红利用其担任药剂科主任的职务便利，接受"李某2"请托，为"李某2"代理的昆药集团血塞通（冻干）、 武汉人福药业有限公司生产的小牛血去蛋白提取物注射液进入医院销售及奥硝唑氯化钠注射液在釆购系统内进行厂家更名等方面提供帮助，并每月在其办公 室内，收受"李某2"所送钱款共计20万元。 （责任编辑：郭文培） ...

Core Insights - The event "I am a Shareholder - Visiting Listed Company Kun Pharmaceutical Group" showcased the company's innovative path, strategic layout, and industrial upgrade achievements, emphasizing its status as a top 100 pharmaceutical enterprise in China [1] Group 1: Cultural Heritage and Innovation - Investors experienced an immersive journey into traditional Chinese medicine culture at Kun Pharmaceutical's subsidiary Kun Traditional Chinese Medicine's museum and intangible cultural heritage experience center, highlighting the company's 640-year development in Yunnan [2] - The museum displayed historical documents, traditional pharmaceutical tools, and local medicinal materials, illustrating Kun Traditional Chinese Medicine's resource advantages in producing high-quality national medicines [2] - The integration of traditional craftsmanship with smart manufacturing was demonstrated, showcasing the preservation of traditional essence while enhancing production efficiency [2] Group 2: Strategic Dialogue and Industry Upgrades - The event featured a dialogue with key executives, including the Secretary-General of the Yunnan Listed Companies Association, emphasizing Kun Pharmaceutical's role as a representative of China's pharmaceutical industry transformation [3] - The company has developed a diversified business structure encompassing traditional Chinese medicine, chemical drugs, and pharmaceutical distribution, with a focus on health products for the aging population [3] Group 3: Investment Focus Areas - Investors expressed interest in three main areas: the silver economy, collaboration with China Resources Sanjiu, and globalization strategies [3] - Kun Pharmaceutical aims to deepen the "medical-nursing integration" model to cater to the growing elderly health market, enhancing product competitiveness through scientific research and rational medication guidance [3] - The company is accelerating its internationalization process, leveraging its global network resources, particularly in artemisinin, and has established sales networks in 60 countries [3] Group 4: Growth Potential and Resilience - An investor noted that Kun Pharmaceutical's strategic layout is both pragmatic and forward-looking, aligning with national policies and market demands, showcasing strong growth potential and resilience [4] Group 5: Conclusion - The event fostered a bridge of trust between industry and capital, highlighting Kun Pharmaceutical's goal of becoming a leader in the silver health industry while advancing its strategic blueprint for high-quality development in China's pharmaceutical sector [5]

Group 1 - The Artemisinin concept index rose by 0.31%, ranking 10th among concept sectors, with three stocks increasing in value, including Delong Huineng, Rundu Co., and Haizheng Pharmaceutical, which rose by 4.35%, 0.87%, and 0.19% respectively [1] - The leading decliners in the sector included Fosun Pharma, New Hecheng, and Baiyunshan, which fell by 1.23%, 0.36%, and 0.34% respectively [1] Group 2 - The main capital flow analysis indicates a net outflow of 176 million yuan from the Artemisinin concept sector, with only one stock, Delong Huineng, experiencing a net inflow of 8.0428 million yuan [2] - The capital flow rankings for the Artemisinin concept show that Delong Huineng had a trading volume of 4.35% and a turnover rate of 13.19%, while other stocks like Kunming Pharmaceutical Group and Rundu Co. had net outflows of 1.72 million yuan and 3.06 million yuan respectively [2][3]

Core Viewpoint - The report from Zhongyin Securities indicates that Kunyu Group's net profit attributable to shareholders for the first three quarters reached 269 million yuan, a year-on-year decrease of 39.42%, with a third-quarter net profit of 71 million yuan, down 59.03% year-on-year [1] Group 1: Financial Performance - Kunyu Group's net profit for the first three quarters was 269 million yuan, reflecting a 39.42% decline compared to the previous year [1] - The net profit for the third quarter alone was 71 million yuan, showing a significant year-on-year decrease of 59.03% [1] Group 2: Business Strategy and Outlook - The company is facing sales pressure due to channel adjustments and is looking forward to improved performance in the coming year [1] - Kunyu Group is enhancing collaboration with China Resources Sanjiu, focusing on the silver economy sector, and is committed to strengthening this partnership [1] - The company is accelerating the integration of offline pharmacies and adapting to online purchasing trends, aiming to build a more efficient business model [1] - Efforts are being made to upgrade the "Kunzhong Medicine" brand and to preheat new product series, with the goal of optimizing inventory, improving sales, and enhancing brand communication [1] - The company is increasing its R&D investment and has a deep layout in the chronic disease sector, which supports a positive long-term development outlook [1]